ORP-101 is a metabolically stable, non-systemic partial agonist of the μ opioid receptor and antagonist of the κ opioid receptor that is designed to mitigate colonic hypersensitivity due to intestinal hyperalgesia and associated motility dysfunction in IBS-D. In multiple clinically relevant animal models ORP-101 has repeatedly been shown to suppress general and colon-specific hyperalgesic signals without CNS penetration and without constriction of the sphincter of Oddi, which could cause acute pancreatitis. ORP-101 is a proprietary molecule fully owned by OrphoMed without any downstream royalties or associated milestone payments.


ORP-102 is a metabolically stable, non-systemic full antagonist of the μ opioid receptor. The dimer is designed to mitigate abdominal distress following chronic exposure to systemic opioids.


ORP-103 is a metabolically stable modulator of intestinal serotonin and norepinephrine to address intestinal motility disorders.


ORP-105 is a non-addictive, centrally-acting, non-opiate analgesic that targets the same receptors as acetaminophen but does not form metabolites that cause liver injury.